Federal Circuit: Antibody-Exception to Written Description Does Not Exist from patentlyo.com By Dennis Crouch Amgen v. Sanofi (Fed. Cir. 2017). The Delaware district court sided with Patentee Amgen and awarded permanent injunctive relief barring Sanofi from selling its injectable drug product Praulent (alirocaumab) – a human monoclonal ...
Share via E–mail | Twitter | Facebook
New WIPO External Auditor, Officers; Vietnam To Chair Assembly; New Treaty Accessions from www.ip-watch.org At the start of the World Intellectual Property Organization General Assembly this week, officers to chair the assemblies of WIPO-managed unions were elected. Following a change of rule last year, a chair was also elected ...
Share via E–mail | Twitter | Facebook
Asia Pacific Countries Challenge Composition Of WIPO Program And Budget Committee from www.ip-watch.org The World Intellectual Property Organization Program and Budget Committee is arguably the most powerful committee of the United Nations agency, and is open to a limited number of countries. This year, the countries sitting on ...
Share via E–mail | Twitter | Facebook
The Imminent Problem of Counterfeit Sports Merchandise from www.iposgoode.ca Counterfeit products are a growing issue and have resulted in an annual estimated loss of $20-30 billion in tax revenue for Canada over the past few years. In particular, the rise in counterfeit sports merchandise ...
Share via E–mail | Twitter | Facebook
A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents from patentlyo.com My Senator (McCaskill) has introduced S. 1948 titled “A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents.” [TribalImmunity] The Bill provides one simple statement as ...
Share via E–mail | Twitter | Facebook
Functional Claiming of Antibodies: (Continue to) Proceed With Caution from www.orangebookblog.com CAFC holds that later-developed antibody species may be evidence that a claimed antibody genus is invalid for lack of written description, and casts doubt on the “antibody exception” Amgen Inc. v. Sanofi, No. 2017-1480 (Fed ...
Share via E–mail | Twitter | Facebook